The offering provides a large cash runway for IDEAYA's pipeline programs, reducing near-term financing risk. However, the 12%+ dilution combined with no disclosed revenue or earnings improvement for the quarter is a negative signal for existing holders. Monitor the company's next pipeline update for trial data that could justify the expanded share count. The 60-day lock-up expiration in early August 2026 may create an overhang if insiders sell into the market.
Price Chart
Executive Summary
IDEAYA Biosciences completed a follow-on public offering on June 10, 2026, selling 7,222,225 shares of common stock and pre-funded warrants to purchase 5,555,576 shares, generating net proceeds of approximately $323.6 million. This is a material dilutive event for a $2.5B market cap company. Stockholders' equity per share is diluted by this issuance, although the ~$323.6M in new cash extends the cash runway for clinical development.
Key Facts
- Sold 7,222,225 shares of common stock at $27.00/share and pre-funded warrants for 5,555,576 shares at $26.9999/warrant.
- Net proceeds of approximately $323.6 million after underwriting discounts and estimated expenses.
- Pre-funded warrants have an exercise price of $0.0001 per share, meaning investors effectively bought common stock exposure at the offering price minus a de minimis exercise price.
- Underwriters' option for 1,666,669 additional shares was exercised in full.
- The offering is dilutive — 7.2 million new common shares (~12%+ dilution pre-warrants exercise) against a pre-offering share base estimated from a $2.5B market cap at $27/share (~92.6M shares outstanding pre-offering), resulting in ~8% dilution from shares alone, plus potential further dilution from warrants.
- Lock-up agreements restrict insider sales for 60 days post-prospectus date.
Financial Impact
Company raised ~$323.6M in net cash. Dilution: 7.2M new shares + 5.6M warrant shares represent roughly 12-14% total potential dilution to existing holders.
Risk Factors
- Significant dilution from new shares and pre-funded warrants (~12-14% total potential dilution).
- No corresponding revenue or earnings catalyst disclosed in this filing.
- 60-day lock-up ends in August, creating potential selling pressure from insiders.
- For a pre-commercial biotech, clinical trial failures would magnify the impact of a larger share base.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-265833 |
| Document: d110954dex41.htm | 0001193125-26-265833 |
| Document: d110954d8k.htm | 0001193125-26-265833 |
| Document: d110954dex51.htm | 0001193125-26-265833 |
| Document: 0001193125-26-265833-index-headers.html | 0001193125-26-265833 |
| Document: 0001193125-26-265833-index.html | 0001193125-26-265833 |
| Document: 0001193125-26-265833.txt | 0001193125-26-265833 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $36.11 $39.95 | ▲ +10.63% | ▲ +11.87% | $37.03 (+2.56%) |
Jun 23, 2026 14w ago | 8-K | $36.28 $35.00 | ▼ −3.53% | ▼ −5.46% | $37.03 (+2.08%) |
Jun 10, 2026 16w ago | 8-K | $28.84 $37.28 | ▼ −29.26% | ▼ −27.37% | $37.03 (−28.42%) |
Jun 9, 2026 16w ago | 424B5 | $27.60 $37.28 | ▼ −35.07% | ▼ −31.45% | $37.03 (−34.18%) |
Jun 8, 2026 16w ago | 424B5 | $28.07 $40.51 | ▼ −44.32% | ▼ −42.87% | $37.03 (−31.94%) |
Jun 3, 2026 17w ago | 8-K | $28.40 $37.65 | ▲ +32.57% | ▲ +33.57% | $37.03 (+30.40%) |
May 5, 2026 21w ago | 8-K | $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $37.03 (+28.86%) |
May 5, 2026 21w ago | 424B5 | $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $37.03 (+28.86%) |
Apr 13, 2026 24w ago | 8-K | $32.82 $28.13 | ▼ −14.29% | ▼ −22.02% | $37.03 (+12.84%) |
Apr 9, 2026 25w ago | 8-K | $31.00 $28.74 | ▼ −7.29% | ▼ −14.86% | $37.03 (+19.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access